Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07312799
Starting soon Phase 1

Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322

NCT07312799 · tracked via the Priya Life Science South Korea tracker
Sponsor
Addpharma Inc
Phase
Phase 1
Started
2026-01-27
Last updated
2025-12-31

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

Treatment A(AD-2321)Treatment B(AD-2322)Treatment C(AD-2321+AD-2322)

Treatment A(AD-2321): AD-2321 Oral Tablet

Treatment B(AD-2322): AD-2322 Oral Tablet

Treatment C(AD-2321+AD-2322): AD-2321 Oral Tablet+AD-2322 Oral Tablet

Study summary

To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.

Eligibility

Sex
ALL
Min age
19 Years
Max age
64 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy adult volunteers aged ≥19 and \<65 years at the time of the screening visit * Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit Exclusion Criteria: * Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied

Primary outcome measure(s)

  • Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss) — pre-dose (0hour) to 24 hours post-dose on Day 14
    AUCτ,ss
  • Maximum concentration of drug in plasma at steady state (Cmax,ss) — pre-dose (0hour) to 24 hours post-dose on Day 14

Trial sites (1)

FacilityCityRegionStatus
H+ Yangji Hospital Seoul South Korea

More Addpharma Inc. trials in South Korea

A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects Starting soon
A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults Starting soon
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C Starting soon
A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male Volunteers Starting soon
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C Starting soon

Other trials for the same condition

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease Recruiting
Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension Recruiting
A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C Starting soon
Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT) Recruiting
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07312799 on ClinicalTrials.gov ↗ ← All trials in South Korea